Viking Therapeutics vs Gilead Sciences: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Viking Therapeutics Inc (VKTX)

Q3 20266 Jul – 24 Sep 2026

▲2▼1

Viking's VK2735 shines, but cash burn and dilution weigh

VK2735 efficacy and dosing VK2735 showed 22% weight loss and up to 97% maintained on less-frequent dosing, strong efficacy plus convenience that positions it against Lilly and Novo.
This is the key new clinical data that drove optimism in the quarter.
Takeover speculation Vertex's $10B Crinetics deal fueled takeover speculation, and an unsettled oral GLP-1 market keeps Viking's pipeline valuable.
This new external event increased investor interest in Viking as a potential acquisition target.
Widening losses and dilution Q2 net loss widened to $128.1M as R&D surged, and an upsized $500M stock and convertible note offering raises dilution concerns.
These new financial developments create a real counterweight to the positive pipeline news.
Long wait and valuation divide Phase 3 data remain years away, and analyst valuations diverge wildly ($92.72 vs. $14.02). Cash burn and funding needs will likely overhang the stock until VK2735 reaches market.
This highlights the ongoing uncertainty and long timeline that keep the stock volatile.

August 20266 Aug – 24 Sep 2026

▲2▼1

Viking's VK2735 data wows, but $500M raise dilutes

VK2735 maintenance data: 22% weight loss, up to 97% kept on less-frequent dosing Viking reported that its obesity drug VK2735 produced 22% weight loss and patients kept up to 97% of it when switched to every-other-week shots (90% monthly), versus 61% on placebo. This is the big driver: strong efficacy plus a more convenient schedule makes the drug a real contender against Lilly and Novo, lifting hopes for future sales and partnership or buyout interest.
This is the single biggest new event moving VKTX, directly boosting its competitive position and long-term value.
Upsized $500M stock and convertible note offering raises dilution worries Viking priced an upsized raise: 7.85 million shares at $35 plus $225 million of convertible notes, up from $200 million each. The cash funds VK2735 and VK3019 trials, but selling new shares dilutes existing owners and the convertible notes could dilute later. This is the main counterweight to the good data.
It is the key new financing event that pressures the stock by diluting current shareholders.
Big pharma GLP-1 race leaves room for Viking Lilly's Mounjaro and Zepbound sales surged while Novo's Ozempic and Wegovy stalled, and Lilly's oral pill Foundayo is just starting. Viking's oral VK2735 phase 3 is planned for late 2026. A fast-growing market with an unsettled oral segment keeps Viking's pipeline valuable, supporting the stock.
It shows the competitive landscape that makes Viking's oral and injectable programs strategically valuable.
Cash burn and capital needs remain the overhang Viking used about $96 million last quarter and cash fell to $502 million from $706 million. Management says cash lasts into 2028, but the new raise confirms trials are expensive. Until VK2735 reaches market, funding needs and dilution risk will keep weighing on the stock even as data improves.
It explains the persistent financial pressure that offsets clinical optimism for VKTX.

Latest6 Aug – 24 Sep 2026

▲2▼1

Viking's VK2735 data wows, but $500M raise dilutes

VK2735 maintenance data: 22% weight loss, up to 97% kept on less-frequent dosing Viking reported that its obesity drug VK2735 produced 22% weight loss and patients kept up to 97% of it when switched to every-other-week shots (90% monthly), versus 61% on placebo. This is the big driver: strong efficacy plus a more convenient schedule makes the drug a real contender against Lilly and Novo, lifting hopes for future sales and partnership or buyout interest.
This is the single biggest new event moving VKTX, directly boosting its competitive position and long-term value.
Upsized $500M stock and convertible note offering raises dilution worries Viking priced an upsized raise: 7.85 million shares at $35 plus $225 million of convertible notes, up from $200 million each. The cash funds VK2735 and VK3019 trials, but selling new shares dilutes existing owners and the convertible notes could dilute later. This is the main counterweight to the good data.
It is the key new financing event that pressures the stock by diluting current shareholders.
Big pharma GLP-1 race leaves room for Viking Lilly's Mounjaro and Zepbound sales surged while Novo's Ozempic and Wegovy stalled, and Lilly's oral pill Foundayo is just starting. Viking's oral VK2735 phase 3 is planned for late 2026. A fast-growing market with an unsettled oral segment keeps Viking's pipeline valuable, supporting the stock.
It shows the competitive landscape that makes Viking's oral and injectable programs strategically valuable.
Cash burn and capital needs remain the overhang Viking used about $96 million last quarter and cash fell to $502 million from $706 million. Management says cash lasts into 2028, but the new raise confirms trials are expensive. Until VK2735 reaches market, funding needs and dilution risk will keep weighing on the stock even as data improves.
It explains the persistent financial pressure that offsets clinical optimism for VKTX.

July 20266 Jul – 30 Jul 2026

▲2▼1

Viking's Obesity Pipeline Advances, But Cash Burn and Valuation Risks Loom

VK2735 Phase 2 Shows Rapid Weight Loss, Phase 3 Data Years Away VK2735 delivered mid-teens percentage weight loss in 13 weeks, faster than oral rivals. Phase 3 results are due mid-to-late 2027, with oral data in 2028-2029. This keeps the potential $100 billion market in play, supporting Viking's valuation, but the long timeline means no near-term revenue.
This is the core clinical update that drives Viking's long-term value and investor optimism.
Vertex's $10B Crinetics Deal Fuels Takeover Speculation for Viking Vertex's acquisition of Crinetics for $10 billion has reignited M&A interest in obesity drugmakers. Viking, with its late-stage VK2735 and early VK3019, is seen as a prime target. A buyout could offer a premium, but any deal depends on upcoming data and remains speculative.
M&A speculation can significantly boost Viking's stock price by implying a potential buyout premium.
Q2 2026 Net Loss Widens to $128.1 Million as R&D Spending Surges Viking reported a $128.1 million net loss, more than double last year's, with R&D expenses up to $115.8 million. Cash fell to $502 million from $706 million. This rising cash burn increases the risk of future dilution or financing, pressuring the stock.
The widening loss and shrinking cash highlight the financial strain of funding late-stage trials, a key risk for a pre-revenue company.
Analyst Valuation Gap: 120% Undervalued vs. DCF Overvalued One analyst narrative sees Viking 120% undervalued at $92.72 per share, while a DCF model suggests it's overvalued at $14.02. This huge discrepancy reflects uncertainty over pipeline success and funding needs, making the stock volatile and hard to value.
The stark valuation divide shows the market's uncertainty about Viking's prospects, which can cause sharp price swings.

6 Jul – 30 Jul 2026

▲2▼1

Viking's Obesity Pipeline Advances, But Cash Burn and Valuation Risks Loom

VK2735 Phase 2 Shows Rapid Weight Loss, Phase 3 Data Years Away VK2735 delivered mid-teens percentage weight loss in 13 weeks, faster than oral rivals. Phase 3 results are due mid-to-late 2027, with oral data in 2028-2029. This keeps the potential $100 billion market in play, supporting Viking's valuation, but the long timeline means no near-term revenue.
This is the core clinical update that drives Viking's long-term value and investor optimism.
Vertex's $10B Crinetics Deal Fuels Takeover Speculation for Viking Vertex's acquisition of Crinetics for $10 billion has reignited M&A interest in obesity drugmakers. Viking, with its late-stage VK2735 and early VK3019, is seen as a prime target. A buyout could offer a premium, but any deal depends on upcoming data and remains speculative.
M&A speculation can significantly boost Viking's stock price by implying a potential buyout premium.
Q2 2026 Net Loss Widens to $128.1 Million as R&D Spending Surges Viking reported a $128.1 million net loss, more than double last year's, with R&D expenses up to $115.8 million. Cash fell to $502 million from $706 million. This rising cash burn increases the risk of future dilution or financing, pressuring the stock.
The widening loss and shrinking cash highlight the financial strain of funding late-stage trials, a key risk for a pre-revenue company.
Analyst Valuation Gap: 120% Undervalued vs. DCF Overvalued One analyst narrative sees Viking 120% undervalued at $92.72 per share, while a DCF model suggests it's overvalued at $14.02. This huge discrepancy reflects uncertainty over pipeline success and funding needs, making the stock volatile and hard to value.
The stark valuation divide shows the market's uncertainty about Viking's prospects, which can cause sharp price swings.

Q2 202623 Jun – 3 Jul 2026

▲4

Viking's Obesity Pipeline Advances as Medicare Coverage Boosts Sector

Medicare GLP-1 Bridge coverage begins Starting July 1, 2026, Medicare's GLP-1 Bridge program covers anti-obesity drugs like Wegovy and Zepbound. This expands the market for weight-loss treatments, boosting demand expectations for Viking's VK2735 if approved. The news helped extend Viking's stock winning streak to eight days.
New Medicare coverage directly expands the addressable market for Viking's obesity drug, a key demand driver.
VK3019 enters first human trial Viking started a Phase 1 trial of VK3019, a new class of weight-loss drug using a different mechanism than GLP-1s. This expands the pipeline beyond VK2735, potentially offering another growth driver. However, it adds development costs for a pre-revenue company.
New clinical milestone for a second obesity candidate diversifies Viking's pipeline and future revenue potential.
VK2735 Phase 3 data expected 2027 Viking's lead obesity drug VK2735 is in Phase 3 trials, with top-line data expected no earlier than 2027. Phase 2 results showed up to 14.7% weight loss, competitive but behind rivals like Eli Lilly's retatrutide (28.3%). Success could unlock a $100 billion market.
The timing and potential of VK2735's Phase 3 data are central to Viking's valuation and investor expectations.
Stock gained 19.2% in June on pipeline optimism Viking shares rose 19.2% in June as investors grew optimistic about the weight-loss pipeline. The rally was fueled by Phase 2 results, pipeline advancements, and sector tailwinds. However, the stock remains volatile and high-risk, with no approved products yet.
Summarizes the period's strong stock performance and the underlying drivers, giving a big-picture view.

June 202623 Jun – 3 Jul 2026

▲4

Viking's Obesity Pipeline Advances as Medicare Coverage Boosts Sector

Medicare GLP-1 Bridge coverage begins Starting July 1, 2026, Medicare's GLP-1 Bridge program covers anti-obesity drugs like Wegovy and Zepbound. This expands the market for weight-loss treatments, boosting demand expectations for Viking's VK2735 if approved. The news helped extend Viking's stock winning streak to eight days.
New Medicare coverage directly expands the addressable market for Viking's obesity drug, a key demand driver.
VK3019 enters first human trial Viking started a Phase 1 trial of VK3019, a new class of weight-loss drug using a different mechanism than GLP-1s. This expands the pipeline beyond VK2735, potentially offering another growth driver. However, it adds development costs for a pre-revenue company.
New clinical milestone for a second obesity candidate diversifies Viking's pipeline and future revenue potential.
VK2735 Phase 3 data expected 2027 Viking's lead obesity drug VK2735 is in Phase 3 trials, with top-line data expected no earlier than 2027. Phase 2 results showed up to 14.7% weight loss, competitive but behind rivals like Eli Lilly's retatrutide (28.3%). Success could unlock a $100 billion market.
The timing and potential of VK2735's Phase 3 data are central to Viking's valuation and investor expectations.
Stock gained 19.2% in June on pipeline optimism Viking shares rose 19.2% in June as investors grew optimistic about the weight-loss pipeline. The rally was fueled by Phase 2 results, pipeline advancements, and sector tailwinds. However, the stock remains volatile and high-risk, with no approved products yet.
Summarizes the period's strong stock performance and the underlying drivers, giving a big-picture view.

23 Jun – 3 Jul 2026

▲4

Viking's Obesity Pipeline Advances as Medicare Coverage Boosts Sector

Medicare GLP-1 Bridge coverage begins Starting July 1, 2026, Medicare's GLP-1 Bridge program covers anti-obesity drugs like Wegovy and Zepbound. This expands the market for weight-loss treatments, boosting demand expectations for Viking's VK2735 if approved. The news helped extend Viking's stock winning streak to eight days.
New Medicare coverage directly expands the addressable market for Viking's obesity drug, a key demand driver.
VK3019 enters first human trial Viking started a Phase 1 trial of VK3019, a new class of weight-loss drug using a different mechanism than GLP-1s. This expands the pipeline beyond VK2735, potentially offering another growth driver. However, it adds development costs for a pre-revenue company.
New clinical milestone for a second obesity candidate diversifies Viking's pipeline and future revenue potential.
VK2735 Phase 3 data expected 2027 Viking's lead obesity drug VK2735 is in Phase 3 trials, with top-line data expected no earlier than 2027. Phase 2 results showed up to 14.7% weight loss, competitive but behind rivals like Eli Lilly's retatrutide (28.3%). Success could unlock a $100 billion market.
The timing and potential of VK2735's Phase 3 data are central to Viking's valuation and investor expectations.
Stock gained 19.2% in June on pipeline optimism Viking shares rose 19.2% in June as investors grew optimistic about the weight-loss pipeline. The rally was fueled by Phase 2 results, pipeline advancements, and sector tailwinds. However, the stock remains volatile and high-risk, with no approved products yet.
Summarizes the period's strong stock performance and the underlying drivers, giving a big-picture view.

Gilead Sciences Inc (GILD)

Q3 20266 Jul – 22 Sep 2026

▲3▼1

Gilead Q3: HIV strength, new launches, but big writedown weighs

Q2 revenue up 10%, HIV sales up 12%, guidance raised Gilead's second-quarter revenue rose 10% to $7.8 billion, with HIV sales up 12%, and the company raised its full-year guidance. This shows the core business is growing and management is more confident about the future.
This is the main positive force behind the stock this quarter, showing stronger sales and a brighter outlook.
Four planned launches and new approvals broaden business beyond HIV Gilead is preparing four new product launches and won approvals for Bixlenvo and a Trodelvy/Keytruda combination. This diversification reduces reliance on HIV and opens new revenue streams, which supports the stock.
It shows concrete progress in expanding beyond HIV, a key part of the bull case this quarter.
Legal win protects Biktarvy; PAHO deal expands lenacapavir access Gilead won a legal case protecting its key HIV drug Biktarvy from generic competition, and signed a deal with PAHO to expand access to lenacapavir. These reduce competitive threats and open new markets, helping the stock.
These events remove a major risk and add a growth avenue, both new this quarter.
$11.2B acquired IPR&D charge causes $8.45 GAAP loss Gilead reported a GAAP loss of $8.45 per share due to an $11.2 billion charge for acquired in-process research and development. This accounting charge weighed on reported earnings, though it doesn't reflect cash flow or ongoing operations.
It is the main negative factor this quarter, explaining why reported earnings looked bad despite strong sales.

September 20265 Sep – 22 Sep 2026

▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.
This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.
PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.
This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.
Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.
Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.
Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.
Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

Latest5 Sep – 22 Sep 2026

▲4

Gilead's HIV franchise strengthens with legal win, access deal, and analyst backing

Fourth Circuit blocks illegal imports of Biktarvy A federal appeals court upheld an injunction stopping foreign versions of Gilead's top HIV drug Biktarvy from being sold in the U.S. This protects Gilead's U.S. sales and pricing power, supporting the stock.
This legal win directly protects Gilead's largest revenue stream and removes a competitive threat.
PAHO deal expands lenacapavir access in Latin America Gilead and the Pan American Health Organization agreed to make HIV prevention drug lenacapavir available in 14 Latin American countries. This widens the market for Gilead's prevention portfolio, though pricing terms are still unclear.
This expands Gilead's global reach for a key growth drug, but the financial impact depends on final pricing.
Morgan Stanley reaffirms Overweight on HIV prevention growth Morgan Stanley kept its buy rating on Gilead, highlighting the HIV prevention franchise. Yeztugo, a twice-yearly shot, is expected to hit $1 billion in first-year sales, with the prevention portfolio at about $4 billion annually and PrEP users more than doubling since 2022.
Analyst backing and concrete sales targets reinforce confidence in Gilead's growth trajectory.
Gilead's pipeline advances with gamgertamig and anito-cel Lakefront Biotherapeutics plans registrational trials in 2027 for gamgertamig, which Gilead will commercialize. Also, Gilead's anito-cel for multiple myeloma has an FDA decision due in December. These add future growth options beyond HIV.
Pipeline progress diversifies Gilead's revenue and offers new catalysts, though they are not yet near-term revenue.

August 202629 Jul – 27 Aug 2026

▲3▼1

Gilead Q2 beat, HIV strength, new drug approvals, but accounting loss

Q2 earnings beat and raised guidance Gilead's second-quarter revenue rose 10% to $7.8 billion, with HIV sales up 12% and PrEP topping $1 billion. The company raised its full-year HIV growth outlook to 9–10%, signaling confidence.
This is the main positive force behind the stock, showing strong operational performance.
New HIV and cancer drug approvals The FDA approved Bixlenvo, a new single-tablet HIV regimen, and the EU expanded Trodelvy plus Keytruda for first-line triple-negative breast cancer. These expand Gilead's product lineup and market reach.
These approvals are new revenue drivers and reinforce Gilead's competitive position.
Large accounting loss from acquisitions Gilead reported a GAAP loss of $8.45 per share due to $11.2 billion in acquired IPR&D charges from Arcellx, Tubulis, and Ouro Medicines. This is an accounting charge, not an operational loss, but it weighed on reported earnings.
This explains the headline loss and why it may not reflect underlying business health.
Analyst confidence and pipeline progress BofA reiterated a Buy rating with a $162 target, and Gilead advanced its pipeline in oncology and a once-weekly oral HIV regimen. However, these pipeline gains are early and not yet near-term revenue.
Analyst support and pipeline advances support the stock, though with limited immediate impact.

15 Aug – 27 Aug 2026

▲4

Gilead's HIV engine accelerates with new drug approvals and raised guidance

HIV sales growth guidance raised to 9–10% Gilead lifted its full-year HIV sales growth outlook to 9–10% from 8%, citing a $4 billion annualized PrEP business and strong Biktarvy. Higher expected sales mean more profit, which supports a higher stock price.
This is a direct, new upgrade to the company's core revenue outlook, a key driver of the stock.
FDA approves Bixlenvo, a new single-tablet HIV regimen The FDA approved Bixlenvo, a once-daily single tablet for complex HIV cases. It is the smallest such option and the first for patients who cannot take existing single-tablet therapies, opening a new market and reinforcing Gilead's HIV leadership.
A new product approval expands the addressable market and future revenue, directly lifting growth prospects.
European Commission expands Trodelvy approval in first-line TNBC The EC approved Trodelvy plus Keytruda for first-line metastatic triple-negative breast cancer, making it the only antibody-drug conjugate plus immunotherapy combo in that setting across the EU. This widens oncology sales and diversifies revenue beyond HIV.
A major regulatory win in a new indication that boosts the oncology franchise and long-term growth.
Pipeline expands with MacroGenics option and once-weekly HIV data Gilead exercised an option on a MacroGenics bispecific cancer program, and positive Phase 3 results for a once-weekly oral HIV regimen with Merck were announced. These add future growth options, though they are early and not yet near-term revenue.
New pipeline additions signal longer-term growth potential, which can support a higher valuation.

29 Jul – 13 Aug 2026

▲3▼1

Gilead's Q2 beat and raised guidance show HIV strength, but acquisition charges hit reported EPS

Q2 revenue beat and raised full-year guidance Gilead reported Q2 revenue of $7.8 billion, up 10% and above estimates, and raised 2026 product sales guidance to $29.8–$30.1 billion. HIV sales rose 12% to $5.7 billion, with Biktarvy up 7%. This shows the core business is growing faster than expected, which supports a higher stock price.
This is the period's central event and directly explains the positive fundamental momentum behind GILD.
PrEP franchise tops $1 billion; Yeztugo persistence strong Quarterly PrEP sales doubled year-over-year to over $1 billion for the first time, led by the twice-yearly shot Yeztugo ($232 million, up 40% from Q1). Over 70% of patients stayed on Yeztugo after a year, the best among PrEP options. This growing prevention business adds a new revenue stream and reduces reliance on HIV treatment alone.
It highlights a key new growth driver that is boosting investor confidence and future sales.
Large acquisition charges push reported EPS deeply negative Gilead's Q2 GAAP EPS was a loss of $8.45, and non-GAAP EPS was a loss of $6.75, due to $11.2 billion in acquired IPR&D expenses from buying Arcellx, Tubulis, and Ouro Medicines. Excluding these one-time charges, EPS would be $8.50–$8.85. The headline loss may scare some investors, but it is an accounting effect, not a cash drain on operations.
It is the main counterweight in the period and explains why reported earnings look bad despite strong operations.
Analyst reiterates Buy; pipeline advances in oncology and HIV BofA reiterated a Buy rating and $162 price target, citing Yeztugo's persistence and raised guidance. Separately, European regulators backed Trodelvy plus Keytruda for first-line triple-negative breast cancer, and a once-weekly oral HIV regimen with Merck met its Phase 3 goals. These expand future sales opportunities.
It shows external validation and pipeline progress that support the stock's longer-term growth story.

July 20266 Jul – 24 Jul 2026

▲4

Gilead's pipeline expands with new launches and positive HIV data

Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.
This is a new strategic update that shows Gilead's growth beyond its core HIV business.
Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.
This is a new clinical milestone that could lead to a new product and boost future sales.
CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.
This is a new regulatory step that could lead to approval and broader use of a key drug.
Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.
This is a new potential use for an existing drug, but the financial impact is not yet clear.

6 Jul – 24 Jul 2026

▲4

Gilead's pipeline expands with new launches and positive HIV data

Four drug launches planned to diversify beyond HIV Gilead is preparing four drug launches this year, including bulevirtide for hepatitis delta and anito-cel for multiple myeloma. This diversification reduces reliance on HIV and opens new revenue streams, supporting the stock.
This is a new strategic update that shows Gilead's growth beyond its core HIV business.
Positive Phase 3 results for once-weekly oral HIV regimen Gilead and Merck reported that a once-weekly oral HIV treatment maintained viral suppression in Phase 3 trials, with higher patient satisfaction. This could become the first once-weekly oral option, strengthening Gilead's HIV portfolio.
This is a new clinical milestone that could lead to a new product and boost future sales.
CHMP recommends Trodelvy plus Keytruda for first-line TNBC The European regulator recommended Trodelvy combined with Keytruda for first-line metastatic triple-negative breast cancer. This expands Trodelvy's use and reinforces its role, potentially increasing sales in Europe.
This is a new regulatory step that could lead to approval and broader use of a key drug.
Remdesivir evaluated in Ebola trial The WHO began an experimental Ebola trial in Congo, testing Gilead's remdesivir. If effective, it could expand remdesivir's use and demand, though the impact is uncertain and likely small.
This is a new potential use for an existing drug, but the financial impact is not yet clear.

Q2 202617 Jun – 26 Jun 2026

▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.
This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.
FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.
This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.
Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.
New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.
Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.
This is a new negative financial disclosure that could cap upside from the positive pipeline news.

June 202617 Jun – 26 Jun 2026

▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.
This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.
FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.
This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.
Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.
New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.
Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.
This is a new negative financial disclosure that could cap upside from the positive pipeline news.

17 Jun – 26 Jun 2026

▲3▼1

Gilead's Trodelvy and HIV pipeline win key approvals, but earnings guidance weighs

FDA and EU approve Trodelvy for first-line triple-negative breast cancer Gilead won U.S. and European approval to use Trodelvy as an initial treatment for metastatic triple-negative breast cancer, a hard-to-treat disease. This opens a much larger patient group and could significantly boost sales, pushing the stock up.
This is a major new approval that expands the market for a key drug, directly lifting future revenue prospects.
FDA accepts filing for once-weekly oral HIV prevention pill The FDA agreed to review Gilead's once-weekly oral PrEP, with a decision expected by February 2027. If approved, it would offer a more convenient option than the current twice-yearly injection, potentially growing the HIV prevention market and lifting GILD.
This regulatory milestone advances a new HIV prevention product, expanding Gilead's HIV franchise.
Positive Phase 3 data for once-weekly oral HIV treatment with Merck Gilead and Merck reported positive late-stage results for a once-weekly oral HIV treatment combining islatravir and lenacapavir. This could simplify HIV therapy and strengthen Gilead's HIV portfolio, supporting the stock.
New clinical success in HIV treatment adds a potential future revenue stream and reinforces Gilead's leadership.
Full-year EPS guidance misses despite revenue beat Gilead's Q1 revenue beat expectations, but its full-year earnings-per-share guidance missed significantly. This suggests cost pressures or lower profitability ahead, which can weigh on the stock even as sales grow.
This is a new negative financial disclosure that could cap upside from the positive pipeline news.